Novocure Ltd (NVCR) is Reiterated by Wedbush to Outperform, Lowers Price Target to $ 20

Novocure Ltd (NVCR) was Reiterated by Wedbush to “Outperform” while Lowering the Price Target of the company shares to $ 20 from a previous price target of $30 . Wedbush advised their investors in a research report released on Jul 29, 2016.

In a different news, on Jun 10, 2016, Michael J. Ambrogi (Chief Operating Officer) sold 20,000 shares at $12.24 per share price. According to the SEC, on Mar 4, 2016, Asaf Danziger (CEO) purchased 10,000 shares at $15.00 per share price. On Mar 4, 2016, Robert J Jr Mylod (director) purchased 20,000 shares at $15.78 per share price, according to the Form-4 filing with the securities and exchange commission.

NovoCure Limited (NovoCure) is a commercial-stage oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields (TTFields) for the treatment of solid tumor cancers. Its TTFields is an anti-mitotic treatment. It also focuses on the clinical trials for the use of TTFields in brain metastases advanced non-small cell lung cancer (NSCLC) pancreatic cancer ovarian cancer and mesothelioma. It is engaged in pipeline development for various indications such as recurrent glioblastoma diagnosed glioblastoma brain metastasis squamous non-small cell lung cancer ovarian cancer pancreatic cancer mesothelioma breast cancer cervical cancer colorectal carcinoma liver metastases malignant melanoma prostate cancer renal adenocarcinoma and urinary transitional cell carcinoma. It offers Optune a TTFields delivery system for use as a monotherapy treatment and NovoTTF-100L for NSCLC.

Novocure Ltd

Leave a Reply

Novocure Ltd - Is it time to Sell?

Top Brokerage Firms are advising their investors on Novocure Ltd. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.